Introduction {#S1}
============

The role played by the immune system in the context of nerve injury and pain is extensive ([@B204]; [@B253]; [@B202]). The two key effector mechanisms of the cellular immune response are inflammation and cytotoxicity. The importance of inflammation has long been recognized. The cardinal signs of inflammation -- calor (warmth), dolor (pain), tumor (swelling), and rubor (redness and hyperemia) -- were first documented by the Roman physician Celsus in the 1st century AD ([@B222]). These symptoms are in large part the product of the actions of inflammatory mediators such as chemokines, cytokines and vasodilators released from immune cells in a process designed to protect and facilitate the repair of injured tissue. The role of cytotoxicity, on the other hand, is to kill living cells and/or degenerate tissues via apoptotic mechanisms and is a critical function of immunity against cancer -- another term introduced to the latin lexicon by Celsus ([@B90]). Pathways leading from immune activation to inflammation and their contribution to the generation of neuropathic pain are relatively well documented ([@B31]). However, recent evidence points to a role of cytotoxicity in the immune response to nerve injury, which can in turn affect pain outcomes ([@B58]).

Neuropathic pain is defined as that arising from a lesion or disease of the somatosensory nervous system ([@B256]; [@B52]). Peripheral neuropathies leading to pain almost invariably result from a partial loss of innervation. This may occur either from disconnection of nerve branches from their peripheral target by physical injury ([@B17]; [@B223]; [@B116]; [@B61]) or a dying-back of axons from their terminals due to metabolic ([@B178]) or chemical neurotoxicity ([@B101]). Axonal loss after injury is characterized by the mechanisms of Wallerian degeneration: a neuron-autonomous (i.e., self-determined) process involving active metabolic signaling within the axon leading to cytoskeletal destabilization and fragmentation ([@B83]; [@B143]). Additionally, dying back of axons utilizes apoptotic pathways, while protecting the cell body from death ([@B288]).

The cellular response to nerve injury involves dedifferentiation of resident Schwann cells, and dynamic infiltration of systemic immune cells ([@B211]). Normally this process would clear the way for axonal regeneration and nerve repair, resulting in transient hypersensitivity followed by recovery. However, interruption of this complex cascade of degeneration and regeneration can lead to aberrant processing which in some cases can transition into chronic pain ([@B286]; [@B58]). Thus, peripheral neuropathies lie at the intersection of multiple degeneration, immune and cell death-related pathways, and how these interact influences pain outcome over time.

NK Cells as Surveyors of Stress and Disease {#S2}
===========================================

Natural killer cells are a key component of the innate immune response ([@B65]), originally identified in the 1970's as a population of large granular lymphocytes. NK cells were found to be spontaneously cytotoxic to freshly isolated cells and many tumor or immortalized cell lines ([@B250]). Toxicity occurred despite the lymphocytes originating from healthy donors, and without the cells being deliberately sensitized. This non-adaptive, non-major histocompatibility complex (MHC)-restricted cytotoxicity was defined as 'natural' cytotoxicity ([@B257]). Later, a system of classification of human cytotoxic lymphocytes was proposed by Lanier and Phillips based on CD3 expression, and whether or not cytotoxicity was MHC restricted ([@B127]), leading to CD8^+^ T cells (CTLs) and natural killer (NK) cells, with NK cells further divided into CD3 positive (NKT) and negative populations. A smaller population of 'unconventional' T cells defined by expression of the gamma and delta (γδ) T cell receptor chains are also capable of cytotoxic functions ([@B41]).

Natural killer cells develop from a lymphoid precursor common to B and T cells, but unlike their adaptive cousins, NK cells lack the machinery for somatic recombination and thus do not generate antigen-specific receptors. NK cells instead possess three main sets of receptors that control target cell recognition: natural killer group 2 (NKG2); killer-cell immunoglobulin-like receptors (KIR) and natural cytotoxicity receptors (NCR). These receptor families inhibit or activate NK cell function through a host of target cell surface ligands ([@B87]). Target cells can undergo loss of MHC-I ligands (known as 'missing-self'), which normally are inhibitory to NK cells, or alternately NK cells can recognize stress-induced ligands expressed by the target cell ('self-recognition'). The net result of these interactions is to allow NK cells to define and subsequently remove transformed or damaged cells ([@B42]).

Critical to NK cell cytotoxicity is the recognition and adhesion to the target cell, forming an 'immune synapse' ([@B59]). Target cell engagement is followed by exocytosis and fusion of lytic granules containing pore-forming perforin proteins and serine proteases such as the granzyme family ([@B96]; [Figure 1](#F1){ref-type="fig"}). NK cells can also induce target cell death signaling via activation of intracellular caspase cascades including tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and Fas (CD95/Apo 1)-mediated apoptosis ([@B297]). In addition, NK cells can effect target cell removal through antibody-dependent cellular cytotoxicity (ADCC) ([@B275]; [Figure 2](#F2){ref-type="fig"}).

![The cytotoxic neuro-immune synapse: Potential downstream intracellular pathways. Cytotoxic natural killer cells form an immunological synapse upon recognition and adhesion to a target, in this case the axon of a stressed sensory neuron. **(1)** Cytotoxic/lytic granules are held by the microtubule organizing center (MTOC) of the NK cell. Immune synapse formation triggers reorientation and polarization of the granules by the MTOC which directs the fusion of the granules to the synaptic membrane. This mechanism ensures the precision release of the cytotoxic contents directly through the targeted axonal membrane. **(2)** The assembly of perforin pore complexes in the axonal membrane from individual perforin subunits released to the extracellular space allows the flow of ions including Ca^2+^, and larger molecules such as the serine protease granzyme B, into the intracellular environment of the target neuron. **(3)** Ca^2+^ flux leads to rapid axon microtubule destabilization and axon degeneration. The full mechanism of cytotoxicity in the axon is unclear. However, in the case of neuron-autonomous Wallerian degeneration, the late-phase Ca^2+^ elevation and subsequent calpain activation required for microtubule destabilization is gated by a metabolic signaling cascade involving depletion of nicotinamide adenine dinucleotide (NAD^+^), activation of Sterile-alpha and armadillo motif containing protein (SARM) and C-Jun N-terminal kinase (JNK) ([@B143]). Although caspase 3 is a major target of granzyme B protease activity ([@B4]), its role in cytotoxic axon degeneration remains unclear. Pathways shown in gray italics are yet to be determined specifically in cytotoxicity-induced axonal degeneration.](fnins-14-00142-g001){#F1}

![The receptors and ligands of cellular cytotoxicity. There are several key cellular effector mechanisms capable of evoking intracellular cell death pathways. In the case of nerve injury this could be a targeted sensory axon. Natural killer (NK) cells are specialist cytotoxic effector cells expressing multiple receptors and ligands for executing cellular cytotoxicity. **(1)** CD95 (Fas) is a transmembrane protein that belongs to the tumor necrosis factor (TNF) family. Engagement with its ligand CD95L (FasL) expressed on NK cells (as well as activated CD8^+^ T cells and plasma cells) triggers apoptotic signaling in the target cell. Apoptosis may also be induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via its receptor on target axons. **(2)** Cross-linking of an antigen-antibody complex with the low affinity Fc receptor FcγRIIIa (CD16a) on human NK cells (FcγRIII/CD16 in mice) can trigger cytotoxic granule release ([@B209]). **(3)** NK cells express a host of activating receptors such as NKG2D which recognize ligands expressed at times of neural stress, tumorigenesis or infection. Cytotoxic activity by either Fc or activator receptor function is kept in balance by inhibitory signaling from major histocompatibility complex (MHC) class I molecules or human leukocyte antigens (HLA), present on nearly all somatic cells; these molecules signal through inhibitory receptors expressed on NK cells, e.g., Ly49 family in mice, and killer immunoglobulin-like receptors (KIR) in humans. **(4)** Macrophages may elicit a form of antibody-dependent cellular phagocytosis (ADCP) via engagement with another low affinity Fc receptor FcγRIIa (CD32a) in humans. Macrophages/monocytes may also express natural killer receptors and ligands allowing them to recognize stressed target cells as well as interact with NK cells via natural killer receptor ligands (e.g., RAE1) while protecting themselves from killing by inhibitory MHC I molecules such as Qa1b (in mice) ([@B298]). **(5)** Sensitized CD8^+^ T cells recognize MHC I-presented antigens at the target membrane surface via corresponding T cell receptors (TCR), which together with co-stimulation via receptors such as NKG2D, triggers cytotoxic granule release in a manner similar to NK cells. CD8^+^ T cells may also trigger apoptosis in target cells via FasL. **(6)** Neutrophils can recognize opsonized targets, such as antibody-antigen complexes, via complement receptors (e.g., C3R) or Fc receptors including FcγRIIa ([@B209]). Complement or antibody Fc receptor signaling neutrophils can lead to respiratory burst and the release of reactive oxygen species (ROS), or an active mechanical disruption of the target cell membrane known as 'trogoptosis' ([@B157]). Signaling via death receptor 6 (DR6) is thought to be involved in axon degeneration in the peripheral nervous system as well as neurodegeneration in the brain but the extrinsic signal for the receptor remains unknown ([@B76]). '**+**' and '**−**' within the immune cell denotes stimulatory and inhibitory signaling, respectively.](fnins-14-00142-g002){#F2}

Human NK cells can be broadly separated into cytotoxic CD56^dim^CD16^+^ cells and cytokine producing CD56^bright^CD16^--^ ([@B191]); the equivalent populations in mice being CD27^--^CD11b^+^ and CD27^+^CD11b^--^, respectively ([@B53]). In addition to cytotoxicity, CD56^bright^ NK cells can shape the immune response in their vicinity by secreting a host of signaling molecules including interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNFα) and colony-stimulating factor 2 (CSF2) ([@B270]; [@B191]) allowing functional interactions with T cells, dendritic cells and macrophages ([@B164]; [@B70]; [@B184]). Unlike other innate immune cells, NK cells are not generally considered phagocytic, although phagocytosis of fungal pathogens by NK cells has been reported ([@B271]).

Two major families of stress-induced ligands for the activatory receptor NKG2 member D (NKG2D) receptor have been identified in humans: MHC class I chain-related protein A (MICA) and B (MICB), and UL16-binding proteins (ULBP1-6), encoded by the family of retinoic acid early transcript 1 (*RAET1*) genes ([@B240]). The homologous ligands in the mouse are separated into three families: Histocompatibility 60 (H-60) ([@B64]), murine UL16-binding protein-like transcript 1 (MULT1) ([@B32]) and the RAE1 proteins family encoded by five *Raet1* genes (α, β, γ, δ and ε) ([@B35]). NKG2D ligands are often expressed by tumors or virally infected cells ([@B87]); for example, influenza infection has been shown to upregulate *Raet1* gene expression in mouse sensory neurons *in vitro* ([@B13]). NKG2D ligands may also be expressed by other cell stressors such as during DNA damage or tissue injury ([@B203]). The *Raet1* gene family (not to be confused with ribonucleic acid export 1, *Rae1*) was originally identified by its expression in a mouse carcinoma cell line in response to retinoic acid treatment ([@B175]).

NK Cells in the Injured Peripheral Nerve {#S3}
========================================

One of the first descriptions of NK cell-mediated neurotoxicity was in sympathetic ganglion neurons following systemic treatment with guanethidine ([@B97]). NK cells harvested from adult mice and stimulated *ex vivo* with the cytokine interleukin-2 (IL-2) were also cytotoxic to dissociated embryonic dorsal root ganglion (DRG) neurons ([@B12]). A clue to the molecular interactions involved was a reduction in DRG cell cytotoxicity by blockade of the NKG2D receptor on NK cells ([@B11]), as well as the high basal expression of *Raet1* in the embryonic sensory neurons ([@B176]), which is likely the result of downstream signaling from retinoic acid. Retinoic acid signaling is critical in neurodevelopment ([@B152]), providing neurotrophic effects on axonal outgrowth ([@B48]) and acting as a regeneration mediator after nerve injury in adult neurons ([@B197]).

In contrast to embryonic neurons, *Raet1* expression is minimal in uninjured adult sensory neurons ([@B12]; [@B58]). Transcripts for *Raet1a, Raet1b* and *Raet1*e, as well as *Ulbp1* (encoding MULT1) and *H60b*, were identified in single DRG neurons isolated from 6 to 8 week old mice, although abundance was low ([@B262]). *Raet1* transcripts are however significantly upregulated in DRG neurons after peripheral nerve injury as detected by whole tissue quantitative-PCR and *in situ* hybridization ([@B58]). The *Raet1e* transcript specifically was also identified by RNA sequencing of mouse DRG, though it did not reach significance as a differentially expressed gene, likely due to the low abundance at the early time points assessed after injury (\<24 h) ([@B212]). Additionally, deep sequencing of the rat sciatic nerve showed significant upregulation of *Raet1* 4 days after crush injury ([@B290]), suggesting either local expression within the injured axon, or additional expression by resident cells within the nerve. Recruitment of NK cells into the injured peripheral nerve ([@B55]; [@B105]; [@B58]) allows for the targeting of RAE1--expressing injured axons for degeneration ([@B58]) as well as possibly targeting other cell types within the nerve ([@B290]).

The signaling process driving *Raet1* expression in injured sensory neurons is currently unclear. RAE1 expression during herpes virus infection occurs via the inhibition of histone deacetylase 3 (HDAC3), which normally acts as constitutive repressor of NKG2D-ligand gene expression ([@B85]). HDAC3 is also exported from the nucleus of injured DRG neurons ([@B44]) contributing to the histone acetylation which is thought to be necessary for 'regeneration associated gene' expression ([@B43]). The potential for autoimmune neurodegeneration by NK cells raises the interesting question of epigenetic influences on NKG2D ligand expression as a possible cause of sensory autoimmune neuropathies ([@B219]). This has been demonstrated in principle by conditional overexpression of *Raet1e* within a population of TRPV1 receptor-positive sensory neurons, which resulted in a loss of heat sensitivity compared to littermate controls, consistent with the absence of peripheral signaling from this important subset of heat-sensitive nociceptive fibers ([@B58]). *Trpv1* expression in the cell bodies of these sensory nerves was preserved, however, suggesting that the effect of *Raet1e* overexpression occurred in the peripheral axons, much like after injury ([@B58]). Further work is required to examine the dynamics of the expression of immune ligands within sensory neurons in health and disease.

NK Cells in Chemically Induced Neuropathies {#S4}
===========================================

Peripheral neuropathy is a common side-effect of many chemotherapeutic agents. Axon degeneration occurs after treatment with oxaliplatin or vincristine, despite differences in the mode of action of these drugs ([@B242]). Oxaliplatin is a platinum-based chemotherapeutic, which blocks tumor cell replication through DNA binding thus leading to apoptosis, but is also associated with significant toxic side-effects including neurotoxicity ([@B183]). Accumulation of oxaliplatin in the DRG specifically is thought to contribute to the symptoms of peripheral sensory neuropathy ([@B241]) with functional changes to nerve excitability early in treatment correlating with the severity of neuropathy over time ([@B187]). Vincristine is a vinca alkaloid drug which binds tubulin, resulting in microtubule destabilization and interruption of mitosis in dividing cells ([@B15]). In sensory neurons, microtubule arrangement alterations are observed particularly in the large myelinated axons of rat sciatic nerves following vincristine treatment but prior to significant axon degeneration ([@B252]). The mechanisms of peripheral neuropathy by vincristine treatment *in vivo* are likely to involve mitochondrial toxicity and disruption of axonal transport ([@B75]). Neuronal microtubules are highly dynamic and participate in the transport of newly synthesized RNA, proteins and organelles required for nerve homeostasis ([@B196]). Disruption of axonal transport will therefore likely affect the local expression of RNA and protein that is critical for the efficient wiring and function of developing and regenerating axons ([@B195]) and likely explains why the longest axons tend to be affected, resulting in a 'stocking and glove' distribution of symptoms at the extremities ([@B242]). Non-neuron-autonomous effects from other cell types including immune cells may also contribute to the neuropathic effect of vincristine ([@B130]).

Chemotherapeutic agents upregulate stress-related proteins in tumor (as well as other) cells, including ligands for NK cells ([@B301]). For example, low-dose chemotherapeutic agents, including oxaliplatin, are capable of upregulating ligands for the activating receptors NKG2D and DNAX accessory molecule-1 (DNAM-1; CD226) and TRAIL in multiple tumor lines leading to enhanced susceptibility to NK cell cytotoxicity ([@B237]; [@B231]). Vincristine and oxaliplatin themselves only mildly impair NK cell cytotoxicity ([@B155]). Chemotherapeutic agents can also enhance NK cell function by down-regulation of inhibitory 'self' ligands on the target cell surface ([@B72]); therefore the sensitivity of tumor or other target cells to NK cell cytotoxicity can be initiated by modulation of activating and inhibitory ligands ([@B198]). Pre-treatment with the cytokine interleukin 2 (IL-2) increases the anti-tumor response rate to oxaliplatin particularly in patients with low blood lymphocyte counts ([@B138]) but there are currently no data available on how this immune modulation may impact on the neuropathic side effects of chemotherapy.

Neurotoxicity of Immunotherapies {#S4.SS1}
--------------------------------

Immunotherapies that recruit cytotoxic effectors cells ([@B45]), such as tumor-targeted monoclonal antibodies (mAbs) and checkpoint inhibitors, are also prone to inducing peripheral neuropathic side-effects ([@B68]; [@B239]) and in rare cases the inflammatory polyneuropathy Guillain-Barré syndrome (GBS) ([@B160]). Tumor targeting by mAbs is fast becoming a mainstay in immunotherapy. Both NK cells and macrophages contribute to ADCC. Binding of the Fc portion of immunoglobulins (IgG) to Fc receptors FcγRIIIa (CD16) or FcγRIIa (CD32) transmits a stimulatory signal to NK cells triggering cytotoxic attack, as well as the release of cytokines such as IFNγ ([@B39]; [Figure 2](#F2){ref-type="fig"}). However, the increased use of mAbs has brought an appreciation of significant side effects, in particular autoimmune disease ([@B91]) and neurological complications ([@B24]). For example, dinutuximab (ch14.18) is a mAb licensed for the treatment for high-risk childhood neuroblastoma and targets the disialosyl glycolipid GD2. NK cells are thought to be the main driver of the anti-tumor effect of neuroblastoma immunotherapy ([@B154]; [@B144]; [@B275]) such that gain of NK cell function is often sought in combination with antibody treatment ([@B118]). The combination of anti-GD2 mAbs with IL-2 improves outcomes in high-risk neuroblastoma patients suggesting that cellular effectors, in particular NK cells, are key to this response ([@B294]). However, during anti-GD2 mAb immunotherapy patients experience significant neuropathic pain ([@B40]) and in severe cases irreversible peripheral sensory neuropathy. Anti-GD2 mAbs recognize the GD2 antigen on axons and affect peripheral nerve function *in vivo* ([@B235]; [@B285]) but how this occurs remains unclear. The anti-tumor effect of anti-GD2 antibodies involves activation of the complement system (complement-dependent cytotoxicity, CDC) in addition to ADCC ([@B108]). Research has until now focused on antibody modifications designed to reduce complement activation, which has had some success in reducing neuropathic side effects in rat models ([@B238]). However, trials with newer mAb isoforms with impaired complement activity still report significant peripheral nerve toxicities ([@B169]; [@B6]; [@B68]), suggesting that other mechanisms of mAb-induced neuropathy are at play ([@B31]). Although immune-mediated inflammation has been proposed as a possible cause of chemotherapy and immunotherapy-induced pain ([@B242]), the role of cellular cytotoxicity in these pathologies requires further investigation.

Axon Degeneration and Cell Death Pathways in Nerve Injury {#S5}
=========================================================

Wallerian degeneration, the process responsible for axonal degeneration following nerve axotomy *in vivo* and in the severed axons of cultured sensory neurons *in vitro*, is an active processes intrinsic to the neuron ([@B148]; [@B190]). The discovery of a spontaneous mouse mutation with delayed or 'slow' Wallerian degeneration (*WldS*) demonstrated that over-activity of the nicotinamide adenine dinucleotide (NAD^+^) biosynthetic enzyme NMNAT1, is sufficient to protect the severed axon from fragmentation ([@B7]; [@B217]). A *Drosophila* screen of axon degeneration after olfactory neuron axotomy led to the identification of dSarm and its mammalian ortholog: Sterile alpha and TIR motif-containing 1 (SARM1) ([@B182]). SARM1 rapidly breaks down NAD^+^ and therefore acts as the key regulator of axonal degeneration after injury ([@B82]; [Figure 1](#F1){ref-type="fig"}). SARM1 has been proposed to be a point of convergence for axonal degeneration associated with chemotherapy ([@B80]) and metabolic neuropathies ([@B258]) but interestingly, not neuronal death ([@B79]).

Axonal loss may also occur in intact neurons by pruning or dying back. These processes share many features with Wallerian degeneration such as disruption of microtubules and cytoskeleton rearrangement ([@B149]). However, in contrast to the Wallerian degeneration of severed axons, axonal pruning during development uses the machinery of apoptosis while avoiding neuronal death via the endogenous caspase inhibitor, X-linked inhibitor of apoptosis protein (XIAP) ([@B261]; [@B288]; [Figure 3](#F3){ref-type="fig"}). The degree of peripheral axon pruning after injury may also be driven by a combination of trophic and axon guidance factors, which also co-opt apoptotic pathways ([@B264]).

![Inhibition of apoptosis in the cell bodies of sensory neurons. Adult sensory neurons are protected from cell death by expression of *Bcl2* (B-cell lymphoma 2). The gene product BCL-2 suppresses the function of the pro-apoptotic protein BAX (BCL2 Associated X) which can be induced by cell death signaling. The expression of further anti-apoptotic genes in the cell bodies of sensory neurons prevent axon degeneration intracellular signaling cascades from causing neuronal death. For example, expression of *Hspb1* (Heat shock protein family B1), also known as HSP27, prevents sensory neuron death after nerve injury. X-linked inhibitor of apoptosis protein (XIAP) prevents cell death during developmental axon pruning by inhibiting caspases in the cell body. Thus axonal activation of caspases 3, 6 and 9, which is sufficient for certain forms of axon-restricted degeneration, occurs in the absence of cell apoptosis ([@B234]; [@B56]).](fnins-14-00142-g003){#F3}

Genes related to programed cell death have long been known to be regulated within the dorsal root ganglia (DRG) of injured sensory neurons ([@B49]). For example, the elevation of pro-apoptotic caspases occurs in injured DRG neurons as well as surrounding non-neuronal glial cells ([@B268]; [@B279]), and single cell analysis of sensory ganglia shows that caspase 3 is upregulated in all sensory neuron subtypes after injury ([@B104]). In fact more than 10 cell death-related genes are among the top 438 genes commonly induced by nerve injury in more than 5 sensory neuron subtypes revealed by single cell gene ontology analysis ([@B205]). Other cell death-related genes, such as programed cell death 2 (*Pdcd2*) are upregulated only in the non-peptidergic (NP) population of nociceptive neurons; conversely, NP neurons showed a *down*-regulation of the neuronal survival related genes ISL LIM homeobox 1 (*Isl1)* and oxidation resistance 1 (*Oxr1*) ([@B104]), suggesting a selective sensitivity of this nociceptive neuron subpopulation to cell-death mechanisms.

While substantial neuronal death can occur in the DRG in neonatal animals after nerve injury ([@B98]), such sensory loss is limited in adults ([@B278]; [@B247]; [@B229]). Nerve injury in young animals (up to 3 weeks of age) results in a reduced expression of the neuroprotective anti-apoptotic gene *Bcl-2* ([@B84]; [@B67]); this developmental period correlates with the lack of neuropathic pain development following peripheral nerve injury ([@B103]; [@B51]; [@B73]). In adults, DRG expression of *Bcl-2* remains high ([@B161]) regardless of nerve injury type ([@B84]). The upregulation of heat shock proteins such as HSP27 (encoded by *Hspb1*) also support neuronal survival after axotomy ([@B50]; [@B132]; [Figure 3](#F3){ref-type="fig"}). Conversely, after peripheral nerve transection, adult mice deficient in the pro-apoptotic gene *Bax* display greater autotomy (self-mutilation) ([@B150]), a sign of ongoing neuropathic pain ([@B17]), suggesting that certain apoptotic or 'cell death'-related pathways may in fact be pain-protective in the face of nerve injury. Similarly, cross-linking of the death receptor Fas (also known as CD95) on sensory neurons enhances neurite outgrowth and nerve regeneration after sciatic nerve crush ([@B62]). Upregulation of Fas ligand within the injured nerve ([@B133]) is therefore likely to have an important bearing on the resolution of nerve injury via non-apoptotic signaling to neurons ([@B62]) and immune cells ([@B281]) in addition to apoptotic mechanisms ([@B133]; [Figure 2](#F2){ref-type="fig"}).

Despite the role of SARM1 as the gate-keeper of intrinsic axon degeneration after injury ([@B63]), extrinsic factors also influence axon degeneration ([@B47]). For example, recent evidence points to the potential of extracellular signaling driving Wallerian degeneration through the orphan death receptor 6 (DR6) ([@B76]). The cytotoxic machinery of NK cells is also well-placed to initiate axon degeneration. Immune-synapse formation with a target cell, followed by perforin pore formation and granzyme entry to the cytoplasm, typically triggers a cascade of calcium-dependent signaling events which in many cell types then leads to apoptosis ([@B255]). In sensory neurons, increases in axonal calcium either through the perforin pore or released from intracellular stores, appears critical to the subsequent localized axon degeneration by NK cells ([@B58]; [Figure 1](#F1){ref-type="fig"}). The ability of calpain inhibitors to prevent axonal degeneration after nerve injury ([@B159]; [@B151]), as well as injury by complement-mediated membrane attack complex (MAC) pore formation ([@B179]), suggests that calcium-dependent processes are sufficient for degeneration. Thus the formation of a 'neuro-immune synapse' and its consequent actions within the axon represents an important extrinsic mechanism of axon degeneration in the periphery ([Figure 1](#F1){ref-type="fig"}). The exact mechanisms downstream from granzyme entry into the axoplasm and how these interact with the known intrinsic pathways of axon degeneration, including SARM1, are currently unknown.

Axon Degeneration and Neuropathic Pain {#S5.SS1}
--------------------------------------

The relationship between axon degeneration and neuropathic pain is complex. Experiments in Wallerian degeneration null mice show that while chronic constriction injury and chemotherapy-induced 'pain' does appear to require axon degeneration ([@B201]; [@B80]), other nerve injury models, such as spinal nerve transection, do not ([@B200]). On the other hand, complete nerve crush injury inducing Wallerian degeneration of the injured axons results in less long-term mechanical hypersensitivity than a partial or 'moderate' crush injury ([@B106]; [@B58]). Thus it appears that axon degeneration is neither necessary nor sufficient for neuropathic pain. Instead, the relative proportion of the injured and uninjured axon fibers and their functional subtypes or modalities is a more likely determining factor, reflective of the fact that most pre-clinical neuropathic pain models are based on a partial injury of the nerve ([@B223]; [@B116]; [@B61]). In addition, neuropathies as a result of physical trauma, metabolic or chemical injury result in an intermediate state of injury between normal and axotomized, as evidenced by the pathological changes observed in axons the absence of complete Wallerian degeneration ([@B252]; [@B187]; [@B106]; [@B58]). Axons in such a 'metastable' state of injury ([@B282]), may also be defined by the expression of cell-stress markers, including immune ligands, on their membranes ([@B58]). These findings suggest that peripheral nerve recovery may be achieved by either axonal stabilization ([@B81]) if intervention is performed early, or by accelerated degeneration if significant injury has already occurred ([@B58]).

Granzymes in Neuropathy {#S6}
=======================

Granzymes are a family of serine proteases produced by cytotoxic NK and T cells that have recently been linked to nerve injury and pain. Granzyme B is detected within the mouse peripheral nerve after transection and crush injuries, of which NK cells are a significant source ([@B58]). *In vitro*, the presence of granzyme B in the culture media is not sufficient to induce DRG axon toxicity, indicating that granzymes are delivered to the axon cytosol by direct contact between cytotoxic cells and sensory nerves ([@B58]). This suggests the formation of a neuro-immune synapse is critical in the neurodegenerative effect of cellular cytotoxicity by NK cells ([Figure 1](#F1){ref-type="fig"}). In clinical neuropathies, granzymes have been labeled in the peripheral nerves ([@B174]; [@B172]), and granzyme B positive lymphocytes are seen in close apposition to neurons in the DRG in the late-stages of Guillain-Barré syndrome (GBS) in which axon degeneration is observed ([@B276]). In the central nervous system (CNS) granzyme B-positive cells can be found next to apoptotic neurons following stroke ([@B36]). Further studies are required to determine the exact role of these cytotoxic effector proteins following nerve injury.

Besides direct cytotoxicity, another potential target for granzymes are protease-activated receptors (PARs), a number of which have been implicated in pain pathogenesis ([@B158]). For example, PAR-4 activation by the serine protease cathepsin G is capable of suppressing sensory neuron excitability ([@B225]). Granzymes have been implicated in pain phenotypes more broadly, for example in a genome wide association study (GWAS) of healthy human twins the gene *GZMM*, encoding granzyme M, was identified as strongly associated to thermal nociception ([@B280]). Conversely, an inhibitor of granzyme B, serpinA3N, is produced by DRG neurons after peripheral nerve injury ([@B266]) where it is thought to attenuate mechanical allodynia in mice by inhibition of another serine protease, leukocyte elastase ([@B267]). Treatment of mice with small molecule inhibitors of leukocyte elastase after nerve injury temporarily reduced established neuropathic mechanical allodynia ([@B14]). Furthermore, serpinA3N is capable of rescuing human fetal neuronal cell death mediated by anti-CD3 and anti-CD28 activated T cells ([@B89]). What role serpinA3N or other serine protease inhibitors may have in mitigating cytotoxic effector functions in the peripheral nerve after injury remains to be explored.

Cellular Conspirators in Axonal Degeneration {#S7}
============================================

Macrophage Cytotoxicity in Nerve Injury {#S7.SS1}
---------------------------------------

Natural killer cells now join macrophages as immune cells participating in the degeneration process after peripheral nerve injury ([@B38]). Macrophages are phagocytic cells that may be tissue resident or originate from the monocyte population of the blood and are an important component of the innate immune response to nerve injury ([@B300]). Macrophages play a key role in the removal and degradation of myelin debris during Wallerian degeneration ([@B243]), and appear capable of degenerating both myelinated and unmyelinated fibers, as liposome depletion of macrophages prior to partial nerve ligation led to a preservation of both fiber types ([@B142]). However, macrophages do not appear capable of overriding the intrinsic delay in Wallerian degeneration in the *WldS* mouse despite their recruitment to the injured nerve ([@B210]). In the absence of frank nerve injury, however, macrophages could play an active role in the peripheral axon degeneration that occurs in aged mice ([@B296]).

Monocytes and macrophages exert cytotoxicity via cell-contact dependent phagocytosis ([@B167]; [@B88]; [Figure 2](#F2){ref-type="fig"}). Neuron morphology may be affected by the phagocytosis of viable axons and dendrites, in a process termed 'neurophagy' ([@B269]). After peripheral nerve injury for example, both central and peripheral projections of primary afferent neurons display signals for phagocytosis by microglia ([@B153]) and macrophages ([@B272]), respectively. Macrophages can recognize the loss of sialic acid residues on membrane-bound glycolipids (desialylation) leading to the removal of neurites by phagocytosis ([@B137]). Neurite phagocytosis by macrophages requires the cell adhesion molecule CD11b, part of the complement C3 receptor (CR3), which recognizes deposition of the complement component C1 on desialyated glycolipids ([@B137]). Thus the complement system works in synergy with innate immunity to mark neuronal membranes for removal. In a model of simian immunodeficiency virus (SIV) infection, monocyte chemotaxis within the DRG led to neuronal loss which correlated the loss of intraepidermal nerve fibers (IENF) ([@B124]). Conversely, sialylation of DRG neuronal cell bodies after injury may help to prevent cytotoxic attack ([@B188]) by engaging inhibitory signaling via SIGLECs (sialic acid-binding immunoglobulin-type lectins) on innate immune cells, including NK cells and monocytes ([@B173]; [@B54]).

Neutrophil Cytotoxicity in Nerve Injury {#S7.SS2}
---------------------------------------

Neutrophils respond to tissue injury within minutes by sensing necrotic cell debris and damage-associated molecular patterns (DAMPs) ([@B274]). Initial contact by patrolling neutrophils results in their death by apoptosis and recruitment of a neutrophil swarm ([@B112]). Neutrophil swarming often leads to collateral damage, although cloaking of the damage site by tissue resident macrophage may help to limit the inflammatory cascade ([@B112]; [@B260]). Neutrophil accumulation requires IL-1 and TNF receptor signaling, probably via IL-1β and TNFα released from resident cells early after injury ([@B168]). Neutrophil depletion experiments confirm their importance in the subsequent development of hyperalgesia after nerve injury ([@B189]; [@B168]). Blockade of CXCL1 cytokine signaling led to a reduction in neutrophil recruitment, and also reduced mechanical hyperalgesia in a model of post-surgical pain ([@B33]) although the source of CXCL1 in the nerve and DRG after injury remains unclear ([@B233]).

Although traditionally known for amplifying the inflammatory response to tissue injury, neutrophils also contribute to tissue repair by the release of growth factors, and polarizing phagocytic macrophages to release anti-inflammatory cytokines such as TGFβ and IL-10 ([@B274]). Neutrophils appear to be critical for regeneration of CNS axons, such as after optic nerve crush ([@B122]), although in the peripheral nervous system no significant deficits in recovery from sciatic nerve injury were observed after neutrophil depletion ([@B168]). More recent evidence suggests that in the absence of infiltrating monocyte-derived macrophages, neutrophils also perform a significant phagocytic role in the injured peripheral nerve ([@B136]).

Neutrophils can release reactive oxygen species (ROS) in a metabolic event known as a respiratory burst, or release of neutrophil extracellular traps (NETs) in a cell death processes known as NETosis. These cytotoxic mechanisms are typically targeted at invading pathogens but may be dysregulated in immune-related disease ([@B186]). A novel form of cytotoxicity enacted by neutrophils has recently been described. Clearance of antibody-coated or 'opsonized' cancer cells, termed 'trogoptosis,' results from target cell membrane disruption leading to necrotic death ([@B157]). Opsonization of peripheral nerve components such as myelin may occur after injury either by coating with IgG ([@B265]) or complement C3 ([@B29]). The C3 receptor (also known as CD11b/CD18) is expressed by NK cells, macrophages, monocytes and granulocytes ([@B9]) as well as neutrophils, where it has been shown to be critical for immune synapse formation and ADCC ([@B263]; [Figure 2](#F2){ref-type="fig"}). Thus the same processes known to mediate phagocytosis of cellular debris in the injured nerve may serve the dual purpose of engaging cell death pathways by infiltrating immune cells.

Schwann Cell Cytotoxicity in Nerve Injury {#S7.SS3}
-----------------------------------------

Schwann cells, which form the myelinating units of the peripheral nerve, respond dynamically within minutes of injury ([@B283]). Schwann cells collaborate with macrophages to phagocytose degenerated myelin after nerve injury utilizing both Tyro3-Axl-Mer (TAM) receptor-mediated and autophagic mechanisms ([@B28]). Recent evidence suggests that Schwann cells may themselves be early participants in peripheral axon degeneration ([@B34]), and delaying dedifferentiation of Schwann cells prolongs the survival of axons after crush injury ([@B34]). The presence of newly discovered Schwann cells adjacent to free nerve endings in the skin are ideally placed to mediate in the dying back of nerve terminals that occurs in multiple peripheral neuropathies ([@B2]). However, the role of Schwann cells in triggering Wallerian degeneration remains unclear.

T Cell Cytotoxicity in Nerve Injury {#S7.SS4}
-----------------------------------

Peripheral nerve injury recruits CD8^+^ T cells to the injured sciatic nerve ([@B105]; [@B14]) where expression of antigen-presenting MHC class I molecules are increased ([@B22]). Although sensory neurons express IFN-γ receptors (typically required for MHC I induction) they fail to upregulate MHC class I in response to IFN-γ signaling ([@B259]). Correspondingly, MHC class I expression in axons of the injured nerve is low ([@B22]). Therefore, the mechanism of CD8^+^ T cell activation by MHC class I induction and antigen presentation after acute nerve injury is unclear. *In vitro*, antigen-specific CD8^+^ T cells are known to cause axonal injury ([@B163]; [@B218]). Lentivirus infection of sensory neurons leads to damage by CD8^+^ T cells via CD40-CD154 mediated signaling ([@B299]). Conversely, trigeminal ganglion neurons infected with herpes simplex virus type I are resistant to apoptosis induced by CD8^+^ T cells ([@B117]), suggesting that the mechanisms controlling T cell mediated neurodegeneration are context dependent.

CD8^+^ T cells (as well as γδ T cells) express the receptor NKG2D and engagement with ligands such as RAE1 augments CD8^+^ T cell function, but only after prior stimulation by antigen-specific T cell receptors (TCRs) ([@B126]), suggesting that NK cells are an important responder to 'stressed-self' in the non-immunized state. NK and CD8^+^ T cells exhibit mutually antagonistic responses to IL-2 immune stimulation ([@B5]) meaning that despite their overlapping cytotoxic roles one or other population will tend to dominate in any given immune response. An example of this is the aberrant expression of RAE1 in pulmonary epithelial cells, which has previously been shown to contribute to chronic obstructive pulmonary disease (COPD) via cytotoxic lymphocytes in an NK but not T-cell dependent manner ([@B23]). Similarly, in the case of peripheral nerve injury NK cells are sufficient for degeneration of axons after IL-2/anti-IL-2 antibody complex stimulation ([@B58]) despite the simultaneous expansion of CD8^+^ T cells ([@B25]). However, additional roles for CD8^+^ T cells within the nerve post-injury cannot be ruled out. Interestingly, resolution of neuropathic pain in mouse models of chemotherapy-induced neuropathy requires CD8^+^ T cells ([@B121]; [@B128]); in these studies the authors propose an indirect involvement of CD8^+^ T cells in suppressing DRG neuron activity by upregulation of IL-10 signaling ([@B121]). T cells are frequently identified in cellular and genetic analysis of peripheral neuropathies ([@B165]; [@B51]; [@B267]; [@B46]) and there is mounting evidence of their involvement in numerous pain states ([@B129]). Whether such an association between pain and T-cells require cytotoxic effector functions remains to be determined.

Evidence of NK Cell Function in Pain Syndromes {#S8}
==============================================

Acute pain (self-administered painful electrical stimulation) transiently increases functional NK cell activity as well as the proportion of NK cells in peripheral blood ([@B86]); this effect was abolished by application of a local anesthetic to the skin, suggesting a neurogenic activation of NK cells ([@B86]). NK cell function can also be stimulated by electro-acupuncture in rats ([@B115]). Peripheral nerve injury increased blood NK cytotoxicity in the 1st week after injury in mice ([@B110]), whereas splenic NK function assessed 3 weeks after nerve ligation was reduced ([@B245]) suggesting a window of time after injury in which NK function is active followed by either recovery or exhaustion.

Gene ontology analysis of differentially expressed genes (DEG) shows significant upregulation of NK cell cytotoxicity-related genes after peripheral nerve injury ([@B51]) and during myelination *in vitro* ([@B284]). Cell senescence in the aging vertebral disc, a risk factor for low back pain, has also recently been associated with a differential expression of NK cell mediated cytotoxicity-related genes ([@B140]). Few studies have directly analyzed NK cells in pain conditions in humans. Low back pain patients presented with a lower percentage of NK cells in peripheral blood than asymptomatic subjects ([@B26]), while recent studies in a similar cohort of chronic lower back pain patients identified an increase in anti-inflammatory T regulatory (T~reg~) cells ([@B147], [@B146]). In the context of tumor immunotherapy, the efficiency of NK cell cytotoxicity benefits from a simultaneous suppression of T~reg~ cell function ([@B171]; [@B139]). Similarly an imbalance in NK and T~reg~ cells leading to loss of NK cell function by the release of immuno-suppressive cytokine such as TGF-β may contribute to low back pain ([@B147], [@B146]). On the other hand, treatment of radicular pain patients with pulsed radiofrequency to the DRG, which led to improved pain outcomes, reduced NK cell frequency in cerebrospinal fluid (CSF) ([@B57]), although peripheral blood counts were not reported.

Immune Phenotyping After Injury or Pain {#S8.SS1}
---------------------------------------

A number of studies have used mass cytometry to assess immune cell subsets, including NK cells, in patients after surgery or trauma. In patients undergoing hip arthroplasty for non-traumatic osteoarthritis NK cells increased 1.6-fold in the blood within an hour of surgical trauma, followed by contraction at 24 and 72 h ([@B78]). In a study of severe trauma patients, NK cells expressing the transcription factor T-bet peaked in the blood 1 day after injury suggesting the recruitment of immature NK cells from the bone marrow ([@B224]). Traumatic brain injury resulted in a higher frequency of inhibitory receptor (KIR2D^+^NKG2A^+^) expressing NK cells in the circulation compared to healthy or major surgery controls, which interestingly correlated with a loss of HLA class I in monocytes and impaired cytotoxicity to missing-self ([@B208]). While these studies suggest a significant alterations of NK cell function in the aftermath of injury, including to the central nervous system, the NK cell phenotype has yet to be explored in patients with defined injury to a peripheral nerve.

Recent studies with more broadly defined chronic pain conditions failed to find an association between NK cell frequencies and pain groups. The percentage of CD56^bright^CD16^+^ cells were slightly increased in patients with broadly defined severe chronic pain, however, generalized NK cell cytotoxic activity and the frequency of the major NK cell subsets were not significantly different ([@B292]). In a study of 14 patients with complex regional pain syndrome (CRPS) and 14 controls, Russo and colleagues used mass cytometry to identify an expansion of both CD4^+^ and CD8^+^ memory T lymphocytes in patients compared to controls ([@B213]). NK cells (defined as CD56^+^ CD19^--^CD3^--^) were more than 50% elevated in CRPS patient blood but this did not reach significance. Thus results from human studies appear to show regulation of NK cells in chronic pain conditions, though the correlation between NK cell function and pain outcomes remains unclear. The inability to assign function from cell numbers alone is likely due to positive and negative effector functions and diverse cell subsets ([@B65]). Appreciation of the differential NK cell subsets that are present in the blood, splenic compartments and injured nerves of mice and humans ([@B53]) will aid further deep phenotyping to build a clearer picture of NK cell function in chronic pain.

There is no difference observed in the numbers of nerve-infiltrating NK cells in rats with mechanical allodynia after injury compared to those without ([@B55]). Furthermore, mice lacking NK cells after chronic depletion maintain a robust development of thermal and mechanical allodynia ([@B58]) in a well characterized model of neuropathic nerve injury ([@B116]). Therefore, NK cells do not appear to be necessary for the development of neuropathic pain. Instead, various factors may affect the pain-resolving potential of NK cells in the period after nerve injury ([@B58]). For example, long-term over-expression of NKG2D ligands such as *Raet1* is known to cause a down-regulation of NK cell receptor expression and loss of function ([@B166]). Additionally, activating ligands may be shed from damaged nerves, preventing their removal by NK cells. For example, cleavage of NKG2D ligands on tumor cells by disintegrins and metalloproteinases (ADAMs) ([@B273]) helps tumors escape immuno-surveillance by NK cells ([@B71]). As well as functions related to extracellular matrix remodeling ([@B291]), matrix metalloproteinases (MMPs) may affect the neuro-immune balance through the regulation of immune ligands on neurons and other cells of the nervous system. Specifically, MMP-9 and MMP-14 are capable of the cleavage of NKG2D ligands ([@B141]; [@B244]) are upregulated after nerve injury and contribute to neuropathic pain in preclinical models ([@B111]; [@B251]). Certain MMP gene variants have also been associated with the risk of low back pain in patients ([@B248]; [@B18]).

Natural killer cell function after nerve injury may also be compromised by morphine, which suppresses both spontaneous and cytokine-stimulated NK cell functions ([@B289]). Immune suppression in response to chronic pain and neurological stress has long been known to affect tumor immunity and mortality ([@B135]). Chronic stress paradigms, including surgical stress, reduces NK cell cytotoxic function in rodents ([@B1]; [@B193]; [@B16]) in an opioid-dependent manner ([@B226]). Immune suppression after traumatic injury in patients, shown to be related to surgical stress ([@B19]; [@B192]), could have an important bearing on pain outcomes by reducing the anti-neuropathic function of cytotoxic effectors.

NK Cell-Macrophage Crosstalk in Pain? {#S9}
=====================================

Macrophages have a recognized involvement in pain hypersensitivity with multiple subtypes persisting within the nerve many months after injury ([@B134]). Depletion of peripheral monocytes/macrophages in mice by systemic treatment with clodronate liposomes reduced degeneration of both myelinated and unmyelinated fibers following nerve injury ([@B142]) and these mice also showed a reduced incidence of pain ([@B142]; [@B46]). Incidence of neuropathic mechanical allodynia was also delayed by macrophage depletion in a rat model of diabetes ([@B162]). Activation of the angiotensin type 2 receptor (AT2R) in macrophages can drive neuropathic pain ([@B228]). The cellular functions of macrophages within the injured nerve may include the production of reactive oxygen species (ROS) leading to nociceptor sensation ([@B227]) as well as inflammatory cytokine production ([@B8]). Inflammatory macrophages (M1) within the nerve are also implicated in pain associated with diabetic neuropathy ([@B214]). M1 skewed macrophages within and around the damaged nerve likely precipitate neuropathic symptoms ([@B113]; [@B214]) and conversely, macrophage polarization to an anti-inflammatory 'M2' phenotype can attenuate neuropathy-induced mechanical hypersensitivity via the production of opioids ([@B114]; [@B185]). Patients with complex regional pain syndrome show an elevation of CD14^+^ CD16^+^ monocytes in their blood ([@B207]) suggesting that altered macrophage function at the systemic level is functionally related to nociplastic pain, i.e., pain that arises from altered nociceptive function in the absence of obvious precipitating cause ([@B10]). Transcriptomic analysis of human DRG from neuropathic pain sufferers suggests that sex differences in pain susceptibility may be driven by differential gene expression in macrophages ([@B177]). Interestingly, the transcriptomic profile of macrophages in mice differs between nerve and DRG compartments ([@B134]), and recent experiments using tissue-targeted macrophage depletion suggest that macrophages in DRG but not the sciatic nerve are required for mechanical allodynia after nerve injury ([@B295]). The divergence of neuropathic pain development in young and adult animals may also be a function of differential functional interactions between macrophage and cells within the DRG ([@B266]) or microglia/T cell signaling in the CNS ([@B236]).

In mice, activated macrophages express NKG2D ([@B298]) suggesting that in addition to NK cells, macrophages may interact with damaged axons via the expression of the ligand RAE1 after traumatic injury ([@B58]; [Figure 2](#F2){ref-type="fig"}). Macrophages and NK cells communicate through a wide variety of cell contact cues and soluble factors ([@B164]). Functional influence is two-way, with macrophages able to either activate or inhibit NK cells ([@B170]; [@B120]), and NK cells capable of killing over-stimulated macrophages ([@B170]). Thus activated NK cells in the immune milieu of the injured nerve may additionally help resolve neuropathic pain by eliminating M1 macrophages ([@B170]) as well as damaged axons ([@B58]).

Endometriosis is another example of a disease that may be influenced by a functional interaction between NK cells and macrophages. Endometriosis is the ectopic growth of endometrial cells forming lesions within the peritoneal cavity surrounding the uterus ([@B246]) leading to chronic pelvic pain and infertility ([@B249]). A higher density of nerve fibers surrounded by macrophages are observed in endometrial lesions relative to surrounding tissue ([@B254]) and growth factor production by these cells has recently been proposed as a key driver of neurogenesis and nerve fiber sensitization in these lesions ([@B74]). Although inflammatory cytokines such as TNFα are elevated in the peritoneal cavity in painful endometriosis ([@B221]), TNFα antagonists are yet to show clinical efficacy ([@B145]). Endometriosis pathophysiology is thought to involve a failure of NK cells to eliminate endometrial lesions from the peritoneal cavity ([@B232]). Peripheral blood and peritoneal NK cells show reduced cytotoxic function in women with endometriosis ([@B77]; [@B249]), and downregulation of NK cell cytotoxic capability via inhibitory interactions with macrophages ([@B287]). Disease severity is correlated with a loss of NK cell cytotoxicity as well as a resistance of the endometrial lesions to NK mediated attack ([@B180]). A failure of NK cell cytotoxicity to target aberrantly sprouting peripheral nerves in the presence of activated macrophages could therefore contribute to the symptoms of this disease. Early clinical trials of recombinant IL-2 treatment in endometriosis showed lower recurrence of pain symptoms ([@B3]), suggesting the potential benefit of the anti-neuropathic function NK cells ([@B58]). A registered trial aimed at assessing the potential use of an inhibitor of programed cell death 1 (PD-1) could lead to an immunotherapeutic treatment for endometriosis^[1](#footnote1){ref-type="fn"}^.

NK Cells in Hematological Malignancies and Inflammatory Neuropathies {#S10}
====================================================================

Interactions between NK cells and peripheral nerves precipitating neuropathy may also occur as a result of transformation of NK cells themselves. A case study in the 1990's first reported an NK cell-specific leukemia with associated peripheral neuropathy presenting as tingling hands and back pain with progressive sensory loss in the extremities ([@B21]); sural nerve biopsy revealed heavy lymphocytic infiltration although NK cell identity could not be confirmed ([@B21]). Later, NK cell lymphoproliferative disease (NK-LPD) was reported as associated with peripheral neuropathy ([@B131]), with steroid treatment improving neurological symptoms concurrent with a reduction in NK cell counts ([@B131]). Prolonged F-wave latencies were consistent with a demyelinating sensorimotor polyneuropathy and sural nerve biopsies revealed an inflammatory neuropathy with myelin loss ([@B131]). Subsequent cases of peripheral neuropathy coincidental to the NK lymphocytosis have been reported ([@B123]; [@B60]; [@B174]). The effectiveness of steroids ([@B131]; [@B215]) or an anti-CD52 antibody targeting a broad population of lymphocytes including NK cells ([@B37]) for the resolution of the peripheral lesions suggests the involvement of cellular immunity in the neurological aspect of the disease ([@B131]). Nerve biopsies within these patients revealed lymphocytic infiltrates ([@B21]; [@B199]) and labeling of granzyme and perforin suggest these cells possess cytotoxic activity ([@B174]). A recent observation of CD3^--^ CD56^+^ cells in cutaneous nerve infiltration secondary to NK-LPD appears to confirm their NK cell identity ([@B172]). A longitudinal study of a severe polyneuropathy was additionally characterized by elevated serum levels of IL-2 and TNFα, as well as increased intrinsic NK cell cytotoxicity ([@B277]).

Overall, 3% of chronic NK-LPD cases appear to go on to develop peripheral neuropathy ([@B194]). The reason for the development of neuropathy with NK cell proliferation in a minority of patients is currently unknown. NK cell leukemia is thought to be caused by a dysregulation of survival signals, including gain-of-function mutations of the transcription factor STAT3, leading to cell proliferation ([@B125]). NK cells from lymphoproliferative disorders possess a skewed pattern of KIR gene expression ([@B100]; [@B66]) suggesting either a propensity for over-activation or loss of constitutive inhibition. Prior infection with Epstein-Barr virus (EBV) is also implicated in the pathogenesis of an aggressive form of NK-LPD ([@B92]; [@B99]) and is itself a known risk-factor for peripheral neuropathy ([@B27]). Prior transformation of the neurons or supporting cells of the nerve may therefore be a pre-requisite for target by NK cells.

Cellular Immunity in Inflammatory Neuropathies {#S10.SS1}
----------------------------------------------

Natural killer cells play an important role in the immune response to infections from EBV, cytomegalovirus (CMV), varicella zoster virus (VZV), and herpes simplex virus (HSV) ([@B181]), and each of these can precipitate peripheral neuropathy ([@B230]; [@B27]). GBS is a rapid-onset autoimmune peripheral neuropathy often preceded by bacterial or viral infection ([@B93]). The most commonly identified prodromal infections are *C. jejuni* (32%), CMV (13%), EBV (10%) and *M. pneumoniae* (5%) ([@B109]). IL-2 is elevated in the serum of GBS patients, with levels returning to normal during the recovery phase ([@B94]). However, NK cell activity is lower than baseline within a week of the onset of neuropathic symptoms in GBS ([@B293]), suggesting exhaustion or loss of NK cell function could exacerbate coincidental neuropathy. Analysis of KIR receptor and human leukocyte antigen (HLA) ligand gene combinations in GBS patients suggests a higher occurrence of inhibitory pairs that would in theory suppress NK cell function ([@B20]). Thus impairment of an otherwise beneficial innate immune response may contribute to the pathogenesis of GBS. This could explain why treatments designed to suppress the cellular immune response, such as corticosteroids, do not significantly reduce and may actually amplify disease severity ([@B107]).

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an inflammatory neuropathy typified by myelin loss and/or axonal damage of bilateral nerves of the extremities. The disease is characterized by a growing list of auto-antibodies found in patient sera that target peripheral nerve components ([@B69]). CIDP autoantibodies may exert a pathogenic effect by directly interrupting the axonal-myelination structure, or complement-dependent cytotoxicity ([@B206]). There is also an appreciation of cellular immune component to CIDP ([@B156]). Both macrophage phagocytosis ([@B119]) and clonal expansion of auto-reactive T cells are thought to play a role in the disease, although direct evidence for a myelin antigen-specific auto-reactive T cell population is currently lacking ([@B220]). Reduced cellular cytotoxicity could also be a risk factor in CIDP. For example, missense loss-of-function mutations in perforin have been identified in some CIDP patients ([@B30]), and a study of 22 CIDP patients and 22 healthy controls showed the proportion of CD3^--^ CD56^+^ NK cells was lower in the blood of patients ([@B216]). CSF from inflammatory neuropathy patients contains elevated NK cells in association with GBS, whereas CD8^+^ T and CD3^+^ NKT cells levels were increased in CIDP patients ([@B95]). These findings suggest that heterogeneity in the cytotoxic cellular immune response could play role in differentiating the acute and chronic forms of inflammatory peripheral neuropathy.

Conclusion {#S11}
==========

Neurobiologists are increasingly aware of the critical role played by immune function and/or dysfunction in pain syndromes ([@B102]). Despite comprising a relatively minor proportion of peripheral blood cells, NK cells appear to play a unique role in the immune response to peripheral nerve activation and injury, enabled by the remarkable specificity of their innate receptor repertoire and the neuro-immune synapse. One beneficial function that these cells would be particularly suited to is the selective pruning of damaged or aberrantly sprouting peripheral axons following injury or disease. As the archetypal cytotoxic immune cell, NK cells have shone a light on the contribution of other immune cells, including macrophages, neutrophils and CD8^+^ T cells, whose cytotoxic potential in the response to nerve injury is yet to be fully elucidated. A number of chronic pain conditions, as well as pain risk-factors including chronic stress and opioid use, are co-morbid with loss of NK cell function, suggesting NK cell modulation as a potential therapy. Developments in the fields of cancer and immunotherapy are already providing tools to tune NK cells and therefore shift the immune response within the damaged nerve from maladaptive to adaptive. However, the potential role of cellular cytotoxicity in the resolution of neuropathic pain must be weighed against cytotoxic mechanisms themselves precipitating injury and therefore augmenting chronic pain. Thus, maintaining a homeostatic balance -- a central tenant of immunology -- remains the priority for immune function, including cellular cytotoxicity by NK and other cells, within the peripheral nerve.
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